Abstract: Methods that use a tobacco product to reduce or mitigate some of the negative effects of tobacco consumption, particularly cancer development are described. The tobacco product contains (a) nicotine, (b) at least one of an isothiocyanate or isothiocyanate precursor, (c) myrosinase and (d) a synthetic isothiocyanate. The product can further include at least one of thymoquinone, resveratrol, synthetic vitamin C, thymoquinone resveratrol and a synthetic vitamin C.

Abstract: A tobacco product reduces or mitigates some of the negative effects of tobacco consumption, particularly cancer development. The tobacco product contains (a) nicotine, (b) at least one of an isothiocyanate or isothiocyanate precursor, (c) myrosinase and (d) a synthetic isothiocyanate. The product can further include at least one of thymoquinone, resveratrol, synthetic vitamin C, thymoquinone resveratrol and a synthetic vitamin C.

Abstract: Methods for generating clinically safe NK cells derived from non-fully differentiated stem cells and their use in treating cancer are provided. The non-fully differentiated stem cells are co-cultured with endogenous NK cells isolated from adipocyte-containing tissue to generate a high percentage of clinically safe NK cells, where anti-tumor activity of the clinically safe NK cells in vitro is similar to that of endogenous NK cells. Optimized Production of the clinically safe autologous NK cells from stem cells provides platform for treating cancer patients by applying an effective adoptive immunotherapy ranging from the early to terminal stages.

Abstract: A composition and a method for generating clinically safe NK cells derived from non-fully differentiated stem cells are provided. The non-fully differentiated stem cells are co-cultured with endogenous NK cells isolated from adipocyte-containing tissue to generate a high percentage of clinically safe NK cells, where anti-tumor activity of the clinically safe NK cells in vitro is similar to that of endogenous NK cells. Optimized Production of the clinically safe autologous NK cells from stem cells provides platform for treating cancer patients by applying an effective adoptive immunotherapy ranging from the early to terminal stages.

Abstract: Methods for reducing or mitigating negative effects of alcohol consumption are described, where a formulation that includes a source of Dihydromycetin (DHM), a source of a milk thistle extract, and a source of Pyrroloquinoline quinone (PQQ) is provided. The source of each DHM and PQQ has at least 95 wt % of the compound. The source of the milk thistle extract has at least 60 wt % silymarin and at least 10 wt % of silybin. The composition is formulated in an orally administrable form consisting of a tablet, a capsule, and an aerosol form. The orally administrable form comprises 10-60 wt % of the DHM, 10-45 wt % of the milk thistle extract, and 0.5-10 wt % of the PQQ in the presence of at least 10 wt % of binder.

Abstract: Induced pluripotent stem cells are treated using a combination of compounds that improve competence of the induced pluripotent stem cells in responding to differentiation signals and/or improve the efficiency of differentiation of the treated induced pluripotent stem cells in differentiation towards a desired phenotype. The combination treatment can incorporate two or more of prolongation of early G1 phase, treatment with an interleukin, modulation of DNA methylation, modulation of histone acetylation, and activation of the Wnt pathway. Cells derived from induced pluripotent stem cells so treated can be used in regenerative therapy and production of organoids.

Abstract: The present invention provides compositions and methods for treating a cancer using liposomes. Collectively, the liposomes contain a protein and a vector encoded for a gene corresponding to the protein. The amount of the protein and the vector a plurality of liposome is sufficiently effective to treat cancer cells. At least some of the liposomes can contain an antibody that recognizes, and thereby targets, a protein expressed on the cancer cell.

Abstract: A composition and a method for generating clinically safe NK cells derived from non-fully differentiated stem cells are provided. The non-fully differentiated stem cells are co-cultured with endogenous NK cells isolated from adipocyte-containing tissue to generate a high percentage of clinically safe NK cells, where anti-tumor activity of the clinically safe NK cells in vitro is similar to that of endogenous NK cells. Optimized Production of the clinically safe autologous NK cells from stem cells provides platform for treating cancer patients by applying an effective adoptive immunotherapy ranging from the early to terminal stages.

Abstract: A tobacco product reduces or mitigates some of the negative effects of tobacco consumption, particularly cancer development. The tobacco product contains (a) nicotine, (b) at least one of an isothiocyanate or isothiocyanate precursor, (c) myrosinase and (d) a synthetic isothiocyanate. The product can further include at least one of thymoquinone, resveratrol, synthetic vitamin C, thymoquinone resveratrol and a synthetic vitamin C.

Abstract: A composition for reducing or mitigating negative effects of alcohol consumption is provided, comprising a source of Dihydromycetin (DHM), a source of a milk thistle extract, and a source of Pyrroloquinoline quinone (PQQ). The source of each DHM and PQQ has at least 95 wt % of the compound. The source of the milk thistle extract has at least 60 wt % silymarin and at least 10 wt % of silybin. The composition is formulated in an orally administrable form consisting of a tablet, a capsule, and an aerosol form. The orally administrable form comprises 10-60 wt % of the DHM, 10-45 wt % of the milk thistle extract, and 0.5-10 wt % of the PQQ in the presence of at least 10 wt % of binder.

Abstract: The present invention provides compositions and methods for inducing pluripotency in non-embryonic and/or somatic cells using exogenous Tb4, exogenous Sox2, and exogenous Oct4. Induced pluripotent stem cells can be can be simian or murine. The exogenous Tb4 can be phosphorylated. At least one of the exogenous Tb4, the exogenous Sox2, and the exogenous Oct4 can be coupled with a cell membrane penetrating moiety and/or a nuclear targeting moiety, allowing them to reach to the nucleus. In addition, the induced pluripotent stem cell maintains pluripotency over at least 100 passages.